Taking stock of most-favored nation deals: how have markets reacted?
{{output}}
Introduction: The Trump Administration has pursued most-favored nation (MFN) drug pricing agreements with major pharmaceutical manufacturers, raising concerns about potential effects on pharmaceutical revenues, profitability, and... ...
